Anne Meade
Psychiatric/Mental Health · Franklin, TNNPI 1861809337
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,430 and has fallen 98.8% since, to $18 in 2025.
Across 111 payments — averaging $13.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$179
- Teva Pharmaceuticals USA, Inc.$170
- Neos Therapeutics, LP$167
- AbbVie$152
- Eisai Inc.$113
- Takeda Pharmaceuticals U.S.A., Inc.$108
- plus $649 from 15 others
What the payments were for
- Food & beverage$1,538100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 14 | $179 |
| Teva Pharmaceuticals USA, Inc. | 17 | $170 |
| Neos Therapeutics, LP | 14 | $167 |
| AbbVie | 10 | $152 |
| Eisai Inc. | 13 | $113 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $108 |
| Sunovion Pharmaceuticals Inc. | 7 | $76 |
| Adlon Therapeutics L.p. | 4 | $74 |
| Supernus Pharmaceuticals, Inc. | 3 | $64 |
| Johnson & Johnson | 3 | $64 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $60 |
| Otsuka America Pharmaceutical, Inc. | 3 | $54 |
| Lundbeck LLC | 3 | $53 |
| Bausch Health US, LLC | 2 | $41 |
| Alkermes, Inc. | 2 | $40 |
| Noven Therapeutics, LLC | 2 | $39 |
| Jazz Pharmaceuticals Inc. | 1 | $23 |
| Novo Nordisk | 1 | $18 |
| Aytu Biopharma, Inc. | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $16 |
| Alfasigma USA, Inc. | 1 | $12 |
How this compares
$1,538 in reported general payments places this provider in the 65th percentile of 1,167 psychiatric/mental health providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lisdexamfetamine Dimesylate | 16 | $2,780 |
| Clonazepam | 29 | $811 |
| Escitalopram Oxalate | 11 | $609 |
| Bupropion XlBupropion Hcl | 15 | $544 |
| Armodafinil | 12 | $239 |
| Alprazolam | 11 | $201 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Franklin
- Shandy McDonaldFranklin$11K
- Stephanie KressFranklin$8K
- Laura MelaroBolivar$682K
- Fay BembryJohnson City$449K
- Kristian DambrinoNashville$449K
- Mary AllenMemphis$422K
- Lauren HansenNashville$263K
- Joshua ThompsonChattanooga$262K
- Kristal HurstBlaine$260K
- Kaitlynn EarlsGreeneville$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.